Rear-view mirrors and crystal balls: A brief reflection on drug discovery

Molecular Interventions

Volumn 8, Issue 2, 2008, Pages 60-63

  Lazo, John S ^a,b  

^a Department of Pharmacology ^*

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DELIVERY SYSTEM; DRUG RESEARCH; DRUG TARGETING; EDITORIAL; MEDICAL RESEARCH; PHARMACOLOGY;

DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; SIGNAL TRANSDUCTION;

EID: 42249096582     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.8.2.1     Document Type: Editorial

References (12)

1. Drews, J. Drug discovery: A historical perspective. Science 287, 1960-1964 (2000).
2. Wong, D.T., Perry, K.W., and Bymaster, F.P. Case history: The discovery of fluoxetine hydrochloride (Prozac). Nature Rev. Drug Discov. 4, 764-774 (2005).
3. Berkowitz, B.A. and Sachs, G. Life cycle of a block buster drug: Discovery and development of omeprazole (Prilosec). Mol. Interv. 2, 6-11 (2002).
4. Rubin, R.P. A brief history of great discoveries in pharmacology: In celebration of the centennial anniversary of the founding of the American Society of Pharmacology and Experimental Therapeutics. Pharmacol. Rev. 59, 289-359 (2007).
5. Monaghan, R.L. and Barrett, J.F. Antibacterial drug discovery. Then, now and the genomics future. Biochem. Pharmacol. 71, 901-909 (2005).
6. Kamb, A., Wee, S., and Lengauer, C. Why is cancer drug discovery so difficult? Nature Rev. Drug Discov. 6, 115-120 (2007).
7. Kola, I., and Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004).
8. Kaelin, Jr, W.G. Choosing anticancer drug targets in the postgenomic era. J. Clin. Invest. 104, 1503-1506 (1999).
9. Foster, B.A., Coffey, H.A., Morin, M.J., and Rastinejad, F. Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510 (1999).
10. Bernal, F., Tyler, A.F., Korsmeyer, S.J., Walensky, L.D., and Verdine, G.L. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J. Am. Chem. Soc. 129, 2456-2457 (2007).
11. Rudolph, J. Inhibiting transient protein-protein interactions: Lessons from the Cdc25 protein tyrosine phosphatases. Nature Rev. Cancer 7, 202-211 (2007).
12. Terstappen, G.C., Schlüpen ,C., Raggiaschi, R., and Gaviraghi, G. Target deconvolution strategies in drug discovery. Nature Rev. Drug Discov. 6, 891-903 (2007).